PRESS RELEASE published on 12/17/2025 at 22:05, 1 month 15 days ago Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques Abivax Obefazimod MICI ECCO 2026 Présentation Orale
PRESS RELEASE published on 12/17/2025 at 22:05, 1 month 15 days ago Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Abivax announces acceptance of 22 abstracts evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, featuring oral presentation on preclinical anti-fibrotic findings Abivax Obefazimod Preclinical Study Inflammatory Bowel Disease ECCO 2026
BRIEF published on 12/15/2025 at 22:10, 1 month 17 days ago Abivax: Third Quarter 2025 Financial Results Financial Results Treasury Abivax Net Loss R&D Expenditures
BRIEF published on 12/15/2025 at 22:10, 1 month 17 days ago Abivax : Résultats financiers du troisième trimestre 2025 Résultats Financiers Abivax Trésorerie Perte Nette Dépenses R&D
BRIEF published on 12/15/2025 at 22:10, 1 month 17 days ago Abivax publie ses résultats financiers du troisième trimestre 2025 Dépenses De R&D Financement Des Biotechnologies Abivax Financials Résultats Du Troisième Trimestre 2025 Position De Trésorerie
BRIEF published on 12/15/2025 at 22:10, 1 month 17 days ago Abivax Reports Third Quarter 2025 Financial Results Cash Position Biotech Funding R&D Expenses Q3 2025 Results Abivax Financials
PRESS RELEASE published on 12/15/2025 at 22:05, 1 month 17 days ago Abivax présente ses résultats financiers du troisième trimestre 2025 Abivax présente ses résultats financiers du troisième trimestre 2025 avec trésorerie de 589,7 millions d'euros et une autonomie financière jusqu'au quatrième trimestre 2027 Résultats Financiers Abivax Troisième Trimestre Autonomie Financière 589,7 Millions D'euros
PRESS RELEASE published on 12/15/2025 at 22:05, 1 month 17 days ago Abivax Presents Third Quarter 2025 Financial Results Abivax presents its third quarter 2025 financial results with EUR 589.7 cash and cash equivalents, providing key updates on its business and operational goals Financial Results Abivax Third Quarter Operational Goals Cash Equivalents
BRIEF published on 12/12/2025 at 18:05, 1 month 20 days ago ABIVAX : Publication des Données Capital et Droits de Vote au 30 Novembre 2025 Droits De Vote Capital Social Abivax Réglementation AMF Informations Financières
BRIEF published on 12/12/2025 at 18:05, 1 month 20 days ago ABIVAX: Publication of Capital and Voting Rights Data as of November 30, 2025 Financial Information Share Capital Voting Rights Abivax AMF Regulations
Published on 02/02/2026 at 00:05, 12 hours 22 minutes ago Resource Upgrade Drilling Begins on Challenger Open Pits
Published on 01/31/2026 at 03:15, 2 days 9 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 2 days 10 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 02/02/2026 at 12:15, 11 minutes ago Monport Laser Celebrates Valentine's Day With the New GT Series MOPA Fiber Laser Technology
Published on 02/02/2026 at 10:48, 1 hour 39 minutes ago EQS-Adhoc: GRAMMER AG exceeds earnings forecast for the 2025 financial year – operating EBIT in Q4 significantly above previous year's level
Published on 02/02/2026 at 08:45, 3 hours 42 minutes ago BAIKOWSKI : Croissance de l’activité en 2025
Published on 02/02/2026 at 07:00, 5 hours 27 minutes ago Entech signe un contrat avec TotalEnergies pour la construction d’un système de stockage hybride éolien de 8MW/8MWh en Guadeloupe
Published on 01/30/2026 at 18:40, 2 days 17 hours ago ICADE - Bilan semestriel du contrat de liquidite